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A B S T R A C T
Quality by Test was the only way to guarantee quality of drug products before FDA launched
current Good Manufacturing Practice.To clearly understand the manufacture processes, FDA
generalized Quality by Design (QbD) in the field of pharmacy, which is based on the thor-
ough understanding of how materials and process parameters affect the quality profile of
final products. The application of QbD in drug formulation and process design is based on
a good understanding of the sources of variability and the manufacture process. In this paper,
the basic knowledge of QbD, the elements of QbD, steps and tools for QbD implementation
in pharmaceutics field, including risk assessment, design of experiment, and process ana-
lytical technology (PAT), are introduced briefly. Moreover, the concrete applications of QbD
in various pharmaceutical related unit operations are summarized and presented.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
While medicine is well known as special goods, the develop-
ment of pharmaceutical industry is based on innovation and
manufacturing. However, there are lots of complaints from phar-
maceutical industry about the strict rules. In current quality by
test (QbT) system (Fig. 1a), product quality is ensured by fol-
lowing a sequence of steps, including rawmaterial testing, fixed
drug product manufacturing process, and end product testing.
It is only when all the specifications of the FDA or other stan-
dards are complied with that the materials can be used for
manufacturing or come into market. If not, they need to be re-
processed. Root causes for failure are usually not well understood
due to the poor process understanding and uncertainty about
how characteristics of substances impacts target product profile.
As a result, themanufacturers have to restart the procedure until
the root causes of failure are understood and addressed or FDA
approves supplements to revise (e.g., widen) the acceptance cri-
teria to pass the previously failed batches [1]. This causes poor
cost-efficiency and product variation, which may lead to poor
drug safety.
Fortunately, with the development of the concept “Quality
by Design (QbD)”, there will be a significant transformation in
pharmaceutical quality regulation, from an empirical process
to a more scientific and risk-based approach. QbD (Fig. 1b) is
a systematic risk-based, proactive approach to pharmaceutical
development that begins with predefined objectives and em-
phasizes product and process understanding and process
control based on sound science and quality risk management.
Comparison between QbT and QbD procedures is shown in
Fig. 1.
* Corresponding author. Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China. Fax: +86 24 23986358.
E-mail address: maoshirui@syphu.edu.cn (S. Mao).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2016.07.006
1818-0876/© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 – 8
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
ScienceDirect
However, although there are some reviews about the theory
of QbD [1,2], the papers about application of different analyti-
cal tools, such as Raman spectroscopy and near-infrared
spectroscopy, in research and development of pharmaceutical
dosage forms are also available [3–6]. References about the ap-
plication of different analytical methods as monitoring tools in
the framework of QbD are not available to the best of our knowl-
edge. Nevertheless, good implementation of QbD in formulation
and process design in pharmaceutical field is highly depen-
dent on a good understanding of the sources of variability and
themanufacture process, and ProcessAnalyticalTechnology (PAT)
is an indispensible tool in the QbD system. Therefore, the ob-
jective of this paper is to provide a whole picture about the
application of QbD in pharmaceutical field by using PAT as a tool.
Except for the basic knowledge of QbD, the elements of QbD,
steps and tools for implementation of QbD in the field of phar-
maceutics, and the applications of QbD in various dosage forms,
which are summarized and presented as guidance. Moreover,
PAT tools applied in different manufacturing processes in the
QbD system have been summarized to provide an insight in the
continuous manufacturing process.
2. Understanding pharmaceutical QbD
To overcome the limitation of GMP, FDA launched cGMP in 2002
[7,8]. cGMP places emphasis on the “software” during themanu-
facturing, namely management level, and specifies staff’s
responsibility strictly and clearly. In contrast, GMP attaches a
great importance on the qualification and training details of
the staff instead of their duties, and these relatively lower re-
quirements are still broadly used in many developing countries.
After the cGMP was carried out, there is still another problem,
that is, in comparison with other industries, such as automo-
bile, aircraft and electronic industries, the specification of
pharmaceutical industry is muchmore rigid and fixed. However,
it is almost impossible to keep all the parameters of the whole
conditions constant and the environment may vary in small
degrees inevitably. Then, the problem is in the approval docu-
ments for a new product to be handed over to FDA, the
company can only write fixed number in the report, as ‘details’
and ‘the authenticity of the process’ are quite critical in cGMP,
it may happen that batches of products fail to meet the rigid
specifications. To solve this problem, the International Con-
ference on Harmonization (ICH) and FDA began to learn from
the other industries, and QbD was introduced into the chemi-
cal manufacturing control (CMC) review pilot program in 2004
with the objective of improving pharmaceutical drug quality
and safety to achieve a desired state for pharmaceutical manu-
facturing on the basis of scientific and engineering knowledge.
The function of QbD, Design Space and real-time release had
been evaluated through the CMC project. Years later, a series
of guidelines was published by ICH: ICH Q8 Pharmaceutical De-
velopment [9], ICH Q9 Quality Risk Management [10], ICH Q10
Pharmaceutical Quality System [11], and the ICH Q11 Devel-
opment and Manufacture of Drug Substances [12].
Quality by Design (QbD) is defined in the ICH Q8 guideline
as ‘a systematic approach to development that begins with pre-
defined objectives and emphasizes product and process
understanding and process control, based on sound science and
quality risk management’ [9], which is in accordance with FDA’s
current drug quality system ideology of ‘quality cannot be tested
into products; it should be built-in or should be by design.’ [13]
2.1. Elements of QbD
There are several statements about the elements of QbD, the
most widely accepted is that, QbD consists of the following pa-
rameters [2,9]:
QualityTarget Product Profile (QTPP): including dosage form,
delivery systems, dosage strength(s), etc. It is a prospective
summary of quality characteristics of a drug product to be
achieved, taking into account dosage strength(s) and con-
tainer closure system of the drug product, together with the
attributes affecting pharmacokinetic characteristics (e.g., dis-
solution, aerodynamic performance) and drug product quality
criteria (e.g., sterility, purity, stability and drug release) appro-
priate for the intended marketed product.
Critical Quality Attributes (CQAs): including physical, chemi-
cal, biological, or microbiological properties or characteristics
of an output material including finished drug product. Poten-
tial drug product CQAs derived from the QTPP and/or prior
knowledge are used to guide the product and process devel-
opment and they should be within an appropriate limit, range,
or distribution to ensure the desired product quality.
Critical Material Attributes (CMAs): including physical, chemi-
cal, biological, or microbiological properties or characteristics
of an input material. CMAs should be within an appropriate
limit, range, or distribution to ensure the desired quality of that
drug substance, excipient, or in-process material.
Critical Process Parameters (CPPs): parameters monitored
before or in process that influence the appearance, impurity,
and yield of final product significantly.
Fig. 1 – Comparison between QbT (a) and QbD (b). (QbT:
quality by test; QbD: quality by design; QTPP: quality target
product profile; CQA: critical quality attributes; CMA:
critical material attributes; CPP: critical process parameters;
DoE: design of experiments).
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During the QbD process, product design and understand-
ing include the identification of CMAs, which are different from
CQAs. CQAs are for output materials while CMAs are for input
materials including drug substance, excipients, in-process ma-
terials. The CQA of an intermediate may become a CMA of the
same intermediate for a downstreammanufacturing step.While
process design and understanding include the identification of
CPPs and a thorough understanding of scale-up principles, linking
CMAs and CPPs to CQAs is of special importance. From the view-
point of QbD, CMAs and CPPs can vary within the established
Design Space without significant influence on CQAs, and as a
result, the quality of the final product will meet the QTPP.
2.2. Steps for Pharmaceutical QbD implementation
As a general rule, the practical implementation of QbD in the
development of new pharmaceutical products can go through
the following steps [1,14,15]:
1. Define the desired performances of the product and iden-
tify the QTPPs;
2. Identification of the CQAs;
3. Identification of possible CMAs and CPPs;
4. Setup and execution of DoE to link CMAs and CPPs to CQAs
and get enough information of how these parameters impact
QTPP.Thereafter, a process Design Space should be defined,
leading to an end product with desired QTPP;
5. Identify and control the sources of variability from the raw
materials and the manufacturing process;
6. Continually monitor and improve themanufacturing process
to assure consistent product quality.
So far, most of the pharmaceutical unit operation pro-
cesses can be optimized by applying the concept of QbD [7].
Each unit operation has its own input material attributes,
process parameters and quality attributes, such as during spray
drying, hot melt extrusion, roller compaction and homogeni-
zation process, as summarized in Table 1.
3. Tools of QbD
The concept of QbD has two components – the science un-
derlying the design and the science of manufacturing. Upon
understanding the elements of QbD and the steps for QbD
implementation, it is important to be familiar with the com-
monly used tools in QbD, including risk assessment, design of
experiment (DoE), and process analytical technology (PAT) [9].
3.1. Risk assessment
Risk assessment is a systematic process of organizing informa-
tion to support a risk decision to be made within a risk
management process. It consists of the identification of hazards
and the analysis and evaluation of risks associated with
exposure to those hazards. It is the first step of quality riskman-
agement process; the other two steps are risk control and risk
review. Risk control includes decision making to reduce and/or
accept risks. The purpose of risk control is to reduce the risk
to an acceptable level. At the final stage, the output/results of
the risk management process should be reviewed to take into
account new knowledge and experience. Throughout the risk
management process, risk communication, the sharing of in-
formation about risk and risk management between the parties
(including regulators and industry, industry and the patient,
within a company, industry or regulatory authority, etc.), should
be ongoing at any stage of the risk management process. The
included informationmight relate to the existence, nature, form,
probability, severity, acceptability, control, treatment, detect-
ability or other aspects of risks to quality [10].
There are three components of risk assessment, that is, risk
identification, risk analysis and risk evaluation. (1) Risk Iden-
tification:The systematic use of information to identify potential
sources of harm (hazards) that are referring to the risk ques-
tion or problem description, which can include historical data,
theoretical analysis, informed opinions, and the concerns of
stakeholders; (2) Risk Analysis: The estimation of the risk as-
sociated with the identified hazards; (3) Risk Evaluation: The
comparison of the estimated risk to given risk criteria using
a quantitative or qualitative scale to determine the signifi-
cance of the risk.
The above components aim at giving answers to the fol-
lowing three questions in the pre-formulation study, (1) What
might go wrong? (2) What is the likelihood (probability) it will
go wrong? (3)What are the consequences (severity)? The evalu-
ation of the risk to quality should be based on scientific
knowledge and ultimately link to the protection of the patient,
the level of effort and formality.
ICH Q9 provides a non-exhaustive list of 9 common riskman-
agement tools as follows [10]: (1) Basic risk management
facilitation methods (Ishikawa fishbone diagram, flowcharts,
check sheets, etc.); (2) Fault tree analysis; (3) Risk ranking and
filtering; (4) Preliminary hazard analysis; (5) Hazard analysis and
critical control points; (6) Failure mode and effects analysis
(FMEA); (7) Failuremode, effects, and criticality analysis (FMECA);
(8) Hazard operability analysis; (9) Supporting statistical tools.
According to the implementation of QbD, risk assessment
has the priority over DoE. Among the tools, Ishikawa fishbone
diagram [26] and FMEA are widely used approaches for risk as-
sessment, either separately [27] or in combination [28]. Taking
the preparation of extruded particles as an example, the
Ishikawa diagram is shown in Fig. 2. The risk factors in the
fishbone diagram are classified into broad categories, while
the FMEA could identify the failure modes that have the great-
est chance of causing product failure, which means each of the
factors in the Ishikawa fishbone diagrams will be ranked later
in the FMEA analysis.The FMEAmethod can be used to perform
the quantitative risk assessment, identifying the CQAs that have
the greatest chance of causing product failure. The outcome
of an FMEA are risk priority numbers (RPN) for each combi-
nation of failure mode severity, occurrence probability, and
likelihood of detection. The RPN is defined as [29]:
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Table 1 – Representative applications of Quality by Design in pharmaceutical unit operations and dosage forms.
Pharmaceutical unit
operations
Dosage form Model drug Design of
experiment (DoE)
Critical material
attributes (CMA)
Critical process
parameters (CPP)
Critical quality
attributes (CQA)
Fluid bed granulation Tablets Not mentioned Fractional factorial design
(screening)
Central composite design
(optimization)
Viscosity, temperature and
concentration of the binder
aqueous dispersion
Inlet air temperature, binder
spray rate and air flow rate
Particle size distribution (PSD),
bulk and tapped densities,
flowability and angle of repose
[16]
Roller compaction Tablets Not mentioned Fractional factorial
statistical design
API composition, API
excipient ratio
API flow rate, lubricant flow
rate, pre-compression
pressure
Tablet weight, tablet dissolution,
hardness, ribbon density [17]
Film coating Coated tablets Placebo tablets Central composite – face
centered –
response surface design
Solid percent of the coating
dispersion
Inlet air temperature, air
flow rate, solid level,
coating pan speed, spray
rate
Appearance (coating defects,
gloss, and color uniformity),
disintegration time (dissolution
of the film coating) [18]
Spray drying Solid nano-crystalline
dry powders
Indomethacin Full factorial design NA Inlet temperature, flow rate,
aspiration rate
Particle size, moisture content,
percent yield, crystallinity [19]
Hot-melt extrusion (HME) Solid lipid
nanoparticles (SLN)
Fenofibrate (FBT) Plackett–Burman (PB)
screening design
Lipid concentration,
surfactant concentration
Screw speed, barrel
temperature, zone of liquid
addition
Particle size, polydispersibility
index, zeta potential,
entrapment efficiency [20]
Homogenization Nanoparticles Paclitaxel Box–Behnken design Surfactant concentration in
aqueous phase (%)
Homogenization rate Average particle size, zeta
potential, encapsulation
efficiency [21]
Solid lipid
nanoparticle (SLN)
Rivastigmine Factorial design Drug: lipid ratio, surfactant
concentration
Homogenization time Size, PDI, entrapment efficiency
[22]
O/W emulsification–solvent
evaporation
Nanoparticles Cyclosporine A
(CyA)
Plackett–Burman (PB)
design
Type of solvent organic to
aqueous phase ratio, drug
concentration, polymer
concentration, surfactant
concentration, O/W ratio
Stirring rate Encapsulation efficiency, particle
size, zeta potential, burst release
and dissolution efficiency [23]
Physical mixture, solvent
evaporation
Controlled-release
tablets
Felodipine Box–Behnken design Amount of polymer HPMC
Amount of polymeric
surfactants, amount of
Pluronic F127
Preparation technique Maximum solubility after
30 min, equilibrium solubility
after 24 h, dissolution efficiency
[24]
Homogenate membrane
method
Orodispersible films Theophylline Central composite design Percentage of HPMC,
percentage of glycerol
Drying temperature Tensile strength, elongation at
break,Young’s modulus,
disintegration time [25]
NA, not available.
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where Occurrence probability (O), Severity (S), and Detectabil-
ity (D) are all expressed with scale 1–5. For Occurrence
probability (O), the number 5 represents likely to occur; number
3 for 50:50 chance of occurring, and number 1 for unlikely to
occur. The Severity (S) is a measure of how severe of an effect
a given failure mode would cause, number 5 means severe
effect, 3 for moderate effect, and 1 for no effect. The Detect-
ability is denoted by parameter D, the more detectable a failure
mode is, the less risk it presents to product quality. For D, similar
to parameter O and S, number 1 means easily detectable,
number 3 for moderately detectable and number 5 repre-
sents hard to detect.
3.2. Design of experiment (DoE)
To carry out the design of experiment, the risk assessment
should be taken into function first. A structured, organized
method for determining the relationship between factors af-
fecting a process and the output of that process is known as
“Design of Experiments” (DoE). DoE is an excellent tool that
allows pharmaceutical scientists to systematically manipu-
late factors according to a pre-specified design. A good design
is based on sound cognition of product and effective manage-
ment of whole process during manufacturing. DoE studies work
together with mechanism-based studies to achieve better
product and process understanding.
DoE is a reasonable method to determine the relationship
between the inputs and outputs of a process. It can help iden-
tify optimal conditions, CMAs, CPPs, and, ultimately, the Design
Space. It is wise to establish a Design Space through DoE for
multivariate experiments. ICH Q8 defines the Design Space as
“the multidimensional combination and interaction of input
variables (e.g., material attributes) and process parameters that
have been demonstrated to provide assurance of quality” [9].
It has been reported that there is no need to hand over supple-
ments to revise (e.g., widen) the acceptance criteria to FDA if
the changes are within the Design Space.
So far, a number of studies have been launched in the drug
delivery systems after QbD initiative was claimed, as summa-
rized in Table 1. It has been demonstrated that DoE is effective
in the design of different dosage forms and unit operations,
it can be used more broadly in the near future to guarantee
high research efficiency with improved product quality.
3.3. PAT as an important tool of QbD
PAT is defined as “Tools and systems that utilize real-timemea-
surements, or rapid measurements during processing, of
evolving quality and performance attributes of in-process ma-
terials to provide information to ensure optimal processing to
produce final product that consistently conforms to estab-
lished quality and performance standards” [10]. ICH Q8 [9]
identifies the use of PAT to ensure that the process remains
within an established Design Space.
The concept originates from the desire of the regulators to
shift control of product quality toward a science-based ap-
proach that explicitly attempts to reduce the risk to patients
by controlling the manufacturing based on understanding of
the process.
From a PAT standpoint, a process is considered well un-
derstood when [26,30]:
(1) All critical sources of variability are identified and
explained;
(2) Variability is managed by the process; and
(3) Product quality attributes can be accurately and reli-
ably predicted.
3.3.1. PAT steps
With the combination of guideline [13] and literatures of Read
et al. [31,32], there is a three-step-process in the design and
optimization of drug formulations and manufacturing pro-
cesses, namely design, analyze and control.
In the design step, experimentation is performed to under-
stand which quality attributes are related to a given unit
operation and which process parameters and raw material at-
tributes have the most impact on the final product quality.This
knowledge is then used to identify the QTPP, CPP and CQA,
which are needed for consideration in the design of an effec-
tive PAT based control scheme for the process.
Fig. 2 – Ishikawa diagram for preparation of extruded particles [12] (reproduced with permission from Elsevier).
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In the analysis step, to identify the chosen quality attri-
bute and process parameters and the raw material attributes,
a process measurement system allows for real time (or near
real time) monitoring of all CQAs and CPPs, using direct or in-
direct analytical methods with appropriate analytical tools.
Finally, control strategies provide adjustments to ensure
control of all critical attributes, and set up the understanding
of relationships among CQAs, CPPs and QTPPs so as to decide
what action to take in case the process performance deviates
from the optimal path or product quality from the desired at-
tributes [33].
3.3.2. PAT tools
For the sake of understanding scientific, risk-managed phar-
maceutical development, manufacture, and quality assurance,
many tools are available in the PAT framework. They can be
categorized into four classes according to the PAT guidance [13]:
(1) Multivariate tools for design, data acquisition and
analysis;
(2) Process analyzers;
(3) Process control tools;
(4) Continuous improvement and knowledge manage-
ment tools.
As defined by FDA’s PAT guidance document, whether to
remove the sample or not, process analysis can be divided into
three categories, namely at-line, on-line and in-line [13]: (1) At-
line: Measurement where the sample is removed, isolated from,
and analyzed in close proximity to the process stream; (2) On-
line: Measurement where the sample is diverted from the
manufacturing process, and may be returned to the process
stream; (3) In-line: Measurement where the sample is not
removed from the process stream and can be invasive or
noninvasive.
It is obvious that PAT is definitely effective in helping QbD
implement. It can do a job of real-time monitoring of process
without interruption to get technological parameters and ma-
terial parameters on-line. PAT enhances understanding of
technology (including the relationship between CQA and CPP),
which leads to accomplishment of quality improvement and
register simplification.
3.3.3. Application of PAT
In most cases, spectroscopic techniques, including Raman spec-
troscopy, UV–VIS spectroscopy, and nuclear magnetic resonance
(NMR), are commonly used. Besides, other PAT analytical
methods, such as Near Infrared spectroscopy (NIR), focused
beam reflectance measurements (FBRM), nanometric tempera-
ture measurement (MTM), tunable diode laser absorption
spectroscopy (TDLAS), are widely applied in the pharmaceu-
tical manufacturing field and play important roles in the real-
time monitoring of the processes, as summarized in Table 2.
Among those PAT tools, NIR has drawn great attention in the
pharmaceutical industry, it is a rapid, non-invasive analytical
technique and there is no need for extensive sample prepara-
tion. NIR has been described in both the United States and the
European Pharmacopeia. It is the most commonly used device
in the manufacturing process, and it has been used for the
identification and characterization of raw materials and inter-
mediates, analysis of dosage forms manufacturing, and
prediction of one or more variables in process streams or final
product streams (composition) on the basis of on-line, in-line
or at-line spectroscopic measurements [40]. Its concrete appli-
cations in different unit operations are exemplified in Table 3.
Due to the complexity of pharmaceutical product-process
design, an efficient and systematic understanding coupled with
an inference system is essential.The real-timemonitoring tools
have increasingly attracted the interests of pharmaceutical
manufacturers. So far, the continuous manufacturing and real-
time monitoring are mostly used in the tablet manufacturing
processes. With the successful application in the tablets, the
PAT tools in other dosage forms manufacturing will soon be
in use.
Table 2 – Representatives of some monitoring tools used in pharmaceutical processes (2011–2015).
Processes Monitoring tool Attributes measured Major outcome
Co-precipitation process Lasentec particle vision
microscopy system PVM819
Nucleation and crystal growth Obtain direct information about the
morphology and size of the co-precipitates [34]
Mammalian cell culture
process
Raman spectroscopy Glycoprotein product yield Selecting which small scale batches are
progressed to large-scale manufacture,
improving process efficiency significantly [35]
Chinese hamster ovary
(CHO) cell fed-batch
process
Fluorescence
excitation–emission
matrix (EEM) spectroscopy
Key fluorophores (e.g. tyrosine,
tryptophan, and the glycoprotein
product)
Quantitative predictive analysis of recombinant
glycoprotein production [36]
Fluid bed granulation Microwave resonance
technology (MRT)
Determine moisture, temperature
and density of the granules
Predict information about the final granule size
[16,37]
Pan coating process New real-time monitoring
tool (PyroButtons)
Record and data in real-time Move with the tablets providing information on
the thermodynamic conditions
(microenvironment) [38]
Continuous direct
compaction tablet
manufacturing process
Near infrared (NIR)
spectroscopy
Powder blend bulk density The NIR spectra are sent to a real time
prediction engine that utilizes the NIR
calibration models for blend density and drug
concentration and a real time prediction tool
(OLUPX) to generate the signals for the control
variables in real time [39]
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4. Conclusion
The fast growth of interest in QbD and its tools indicates that
the approaches are not fashionable phenomena but responses
to the demands of modernmanufacturing process. QbD is a cost
and time efficient approach in design and manufacturing, with
DoE, risk assessment, and PAT as its tools to achieve a better
understanding on the materials and processes, which make the
QbD available and feasible to the pharmaceutical field.With its
broad implementation in the pharmaceutical manufacture, drug
products with high and reproducible quality can be antici-
pated. Moreover, QbD has become a broadly applicable
manufacturing model and is going far beyond pharmaceutical
(or related) areas.
Acknowledgements
This project is financially supported by Talents Project of Lia-
oning Province, China (LR2013047).
R E F E R E N C E S
[1] Yu LX. Pharmaceutical quality by design: product and
process development, understanding, and control. Pharm
Res 2008;25(4):781–791.
[2] Yu LX, Amidon G, Khan MA, et al. Understanding
pharmaceutical quality by design. AAPS J 2014;16(4):771–783.
[3] De Beer T, Burggraeve A, Fonteyne M, et al. Near infrared
and Raman spectroscopy for the in-process monitoring of
pharmaceutical production processes. Int J Pharm
2011;417(1–2):32–47.
[4] Jamrogiewicz M. Application of the near-infrared
spectroscopy in the pharmaceutical technology. J Pharm
Biomed Anal 2012;66:1–10.
[5] Paudel A, Raijada D, Rantanen J. Raman spectroscopy in
pharmaceutical product design. Adv Drug Deliv Rev
2015;89:3–20.
[6] Gordon KC, McGoverin CM. Raman mapping of
pharmaceuticals. Int J Pharm 2011;417(1–2):151–162.
[7] Food and Drug Administration. Pharmaceutical current
Good Manufacturing Practices (cGMPs) for the 21st century –
A risk-based approach. 2002.
[8] Food and Drug Administration. Pharmaceutical cGMPs for
the 21st century – A risk based approach: second progress
report and implementation plan. 2003.
[9] International Conference on Harmonization (ICH). Guidance
for industry: Q8 (R2) pharmaceutical development, ICH
harmonised tripartite guideline, step 4. 2009.
[10] International Conference on Harmonization (ICH). Guidance
for industry: Q9 quality risk management, ICH harmonised
tripartite guideline, step 4. 2005.
[11] International Conference on Harmonization (ICH). Guidance
for industry: Q10 quality systems approach to
pharmaceutical CGMP regulations, ICH harmonised
tripartite guideline, step 4. 2008.
[12] International Conference on Harmonization (ICH). Guidance
for industry: Q11 development and manufacture of drug
substances (chemical entities and biotechnological/
biological entities), ICH harmonised tripartite guideline, step
4. 2012.
[13] US Department of Health and Human Services, Food and
Drug Administration (FDA), Center for Drug Evaluation and
Research (CDER), et al. PAT guidance for industry – A
framework for innovative pharmaceutical development,
manufacturing and quality assurance. 2004.
[14] Tomba E, Facco P, Bezzo F, et al. Latent variable modeling to
assist the implementation of quality-by-design paradigms in
pharmaceutical development and manufacturing: a review.
Int J Pharm 2013;457(1):283–297.
[15] Rathore AS. Roadmap for implementation of quality by
design (QbD) for biotechnology products. Trends Biotechnol
2009;27(9):546–553.
[16] Lourenço V, Lochmann D, Reich G, et al. A quality by
design study applied to an industrial pharmaceutical fluid
bed granulation. Eur J Pharm Biopharm 2012;81(2):438–
447.
[17] Singh R, Ierapetritou M, Ramachandran R. An engineering
study on the enhanced control and operation of continuous
manufacturing of pharmaceutical tablets via roller
compaction. Int J Pharm 2012;438(1–2):307–326.
[18] Teckoe J, Mascaro T, Farrell TP, et al. Process optimization of
a novel immediate release film coating system using QbD
principles. AAPS PharmSciTech 2013;14(2):531–540.
[19] Kumar S, Gokhale R, Burgess DJ. Quality by design approach
to spray drying processing of crystalline nanosuspensions.
Int J Pharm 2014;464(1–2):234–242.
[20] Patil H, Feng X, Ye X, et al. Continuous production of
fenofibrate solid lipid nanoparticles by hot-melt extrusion
technology: a systematic study based on a quality by design
approach. AAPS J 2015;17(1):194–205.
[21] Yerlikaya F, Ozgen A, Vural I, et al. Development and
evaluation of paclitaxel nanoparticles using a Quality-by-
design approach. J Pharm Sci 2013;102(10):3748–3761.
Table 3 – Representative applications of near infrared spectroscopy (NIR) in representative unit operations.
Unit operations Parameters Description
Crystallization Polymorphism and particle size of the indomethacin powder In-line [41]
Determine API and residual solvent contents On-line [42]
Co-precipitation Turbidity monitoring, and in situ crystal size monitoring On-line [43]
Freeze-drying Moisture content analysis In-line [44]
Hot-melt extrusion Screw speed and drug loading In-line [45]
Powder mixing Monitor blending uniformity In-line [28]
Compression Content uniformity On-line [46]
Continuous granulation process Show the variation in solid state (transform anhydrous theophylline to
theophylline monohydrate)
In-line [47]
Fluidized bed granulation Determine the moisture content, size distribution, and bulk density In-line [48]
Fluid-bed coating Film thickness on pharmaceutical pellets In-line [49]
7a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 – 8
[22] Shah B, Khunt D, Bhatt H, et al. Application of quality by
design approach for intranasal delivery of rivastigmine
loaded solid lipid nanoparticles: effect on formulation and
characterization parameters. Eur J Pharm Sci 2015;78:54–
66.
[23] Rahman Z, Zidan AS, Habib MJ, et al. Understanding the
quality of protein loaded PLGA nanoparticles variability by
Plackett–Burman design. Int J Pharm 2010;389(1–2):186–
194.
[24] Basalious EB, El-Sebaie W, El-Gazayerly O. Application of
pharmaceutical QbD for enhancement of the solubility and
dissolution of a Class II BCS drug using polymeric
surfactants and crystallization inhibitors: development of
controlled-release tablets. AAPS PharmSciTech
2011;12(3):799–810.
[25] Visser JC, Dohmen WMC, Hinrichs WLJ, et al. Quality by
design approach for optimizing the formulation and
physical properties of extemporaneously prepared
orodispersible films. Int J Pharm 2015;485(1–2):70–76.
[26] Patwardhan K, Asgarzadeh F, Dassinger T, et al. A quality by
design approach to understand formulation and process
variability in pharmaceutical melt extrusion processes. J
Pharm Pharmacol 2015;67(5):673–684.
[27] Bousses C, Ferey L, Vedrines E, et al. Using an innovative
combination of quality-by-design and green analytical
chemistry approaches for the development of a stability
indicating UHPLC method in pharmaceutical products. J
Pharm Biomed Anal 2015;115:114–122.
[28] Corredor CC, Lozano R, Bu X, et al. Analytical method quality
by design for an on-line near-infrared method to monitor
blend potency and uniformity. J Pharm Innov 2015;10(1):47–
55.
[29] Fahmy R, Kona R, Dandu R, et al. Quality by design I:
application of failure mode effect analysis (FMEA) and
Plackett–Burman design of experiments in the identification
of “main factors” in the formulation and process design
space for roller-compacted ciprofloxacin hydrochloride
immediate-release tablets. AAPS PharmSciTech
2012;13(4):1243–1254.
[30] Rao G, Moreira A, Brorson K. Disposable bioprocessing:
the future has arrived. Biotechnol Bioeng 2009;102(2):348–
356.
[31] Read EK, Park JT, Shah RB, et al. Process analytical
technology (PAT) for biopharmaceutical products: part I.
Concepts and applications. Biotechnol Bioeng
2010;105(2):276–284.
[32] Read EK, Shah RB, Riley BS, et al. Process analytical
technology (PAT) for biopharmaceutical products: part II.
Concepts and applications. Biotechnol Bioeng
2010;105(2):285–295.
[33] Orlandini S, Pinzauti S, Furlanetto S. Application of quality
by design to the development of analytical separation
methods. Anal Bioanal Chem 2013;405(2–3):443–450.
[34] Wu H, White M, Khan MA. Quality-by-Design (QbD): an
integrated process analytical technology (PAT) approach for
a dynamic pharmaceutical co-precipitation process
characterization and process design space development. Int
J Pharm 2011;405(1–2):63–78.
[35] Li B, Ray BH, Leister KJ, et al. Performance monitoring of a
mammalian cell based bioprocess using Raman
spectroscopy. Anal Chim Acta 2013;796:84–91.
[36] Li B, Shanahan M, Calvet A, et al. Comprehensive,
quantitative bioprocess productivity monitoring using
fluorescence EEM spectroscopy and chemometrics. Analyst
2014;139(7):1661–1671.
[37] Lourenco V, Herdling T, Reich G, et al. Combining microwave
resonance technology to multivariate data analysis as a
novel PAT tool to improve process understanding in fluid
bed granulation. Eur J Pharm Biopharm 2011;78(3):513–521.
[38] Pandey P, Bindra DS. A commentary on scale-up of pan
coating process using microenvironmental control. J Pharm
Sci 2014;103(11):3412–3415.
[39] Singh R, Roman-Ospino AD, Romanach RJ, et al. Real time
monitoring of powder blend bulk density for coupled feed-
forward/feed-back control of a continuous direct
compaction tablet manufacturing process. Int J Pharm
2015;495(1):612–625.
[40] Reich G. Near-infrared spectroscopy and imaging: basic
principles and pharmaceutical applications. Adv Drug Deliv
Rev 2005;57:1109–1143.
[41] Lee H-E, Lee M-J, Kim W-S, et al. In-line monitoring and
interpretation of an indomethacin anti-solvent
crystallization process by near-infrared spectroscopy (NIRS).
Int J Pharm 2011;420(2):274–281.
[42] Schaefer C, Clicq D, Lecomte C, et al. A process analytical
technology (PAT) approach to control a new API
manufacturing process: development, validation and
implementation. Talanta 2014;120:114–125.
[43] Wu H, Khan MA. Quality-by-design (QbD): an integrated
process analytical technology (PAT) approach for real-time
monitoring and mapping the state of a pharmaceutical
coprecipitation process. J Pharm Sci 2010;99(3):1516–1534.
[44] Kauppinen A, Toiviainen M, Lehtonen M, et al. Validation of
a multipoint near-infrared spectroscopy method for in-line
moisture content analysis during freeze-drying. J Pharm
Biomed Anal 2014;95:229–237.
[45] Islam MT, Maniruzzaman M, Halsey SA, et al. Development
of sustained-release formulations processed by hot-melt
extrusion by using a quality-by-design approach. Drug Deliv
Transl Res 2014;4(4):377–387.
[46] Sulub Y, LoBrutto R, Vivilecchia R, et al. Content uniformity
determination of pharmaceutical tablets using five near-
infrared reflectance spectrometers: a process analytical
technology (PAT) approach using robust multivariate
calibration transfer algorithms. Anal Chim Acta
2008;611(2):143–150.
[47] Fonteyne M, Vercruysse J, Diaz DC, et al. Real-time
assessment of critical quality attributes of a continuous
granulation process. Pharm Dev Technol 2013;18(1):85–97.
[48] Burggraeve A, Monteyne T, Vervaet C, et al. Process
analytical tools for monitoring, understanding, and control
of pharmaceutical fluidized bed granulation: a review. Eur J
Pharm Biopharm 2013;83(1):2–15.
[49] Lee MJ, Seo DY, Lee HE, et al. In line NIR quantification of
film thickness on pharmaceutical pellets during a fluid bed
coating process. Int J Pharm 2011;403(1–2):66–72.
8 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 – 8
